BACKGROUND: The American Heart Association (AHA), in conjunction with the National
Institutes of Health, annually reports the most up-to-date statistics related to heart disease …

Balancing stroke prevention and risk of bleeding in patients with atrial fibrillation (AF) is
challenging. Direct oral anticoagulants (DOACs) are by now considered standard of care for …

Purpose Pharmacodynamic drug-drug interactions (PD DDIs) may influence the safety of
non-vitamin K antagonist oral anticoagulants (NOACs), but the extent to which PD DDIs …

Background Patients with atrial fibrillation have a relevant risk for ischemic stroke despite the
recommended use of direct oral anticoagulants (DOAC). The risk correlates with the …

Background The DOAC score has been recently proposed for bleeding risk stratification of
patients with atrial fibrillation treated with direct oral anticoagulants (DOAC). Objective To …

Purpose Over the last decade, the use of direct oral anticoagulants (DOACs) has strongly
increased. We aimed to describe and compare risk profiles including potential changes over …

Aims Direct oral anticoagulants (DOAC) are progressively replacing vitamin K antagonists in
the prevention of thromboembolism in patients with atrial fibrillation. However, their real …

Background Venous thromboembolism (VTE) and arterial thromboembolism (ATE) are
considered as two separate disease-entities. In recent years, studies have reported clear …

Abstract Background Vitamin‐K antagonists (VKAs) have widely been replaced by non‐VKA
oral anticoagulants (NOACs). This includes Austria, Germany and Switzerland, where as …

Background Lung transplantation (LTx) is the definitive treatment for end-stage lung failure.
However, there have been no large, long-term studies on the impact of acute in-hospital …